Baxter International Inc. appointed John Rogers as Executive Vice President and Chief Financial Officer, effective October 1, 2026. Rogers joins from Smith+Nephew plc, where he served as CFO since 2024. His compensation includes a $925,000 base salary, a target bonus of 100% of base, and an annual equity grant value of $4 million. He will also receive a sign-on bonus of approximately $2.83 million to replace prior employer incentives. Interim CFO Anita Zielinski departs September 15, 2026, with CEO Andrew Hider serving as interim CFO until Rogers starts. Bernie Heine is appointed interim Chief Accounting Officer and Controller effective September 15, 2026, receiving a $15,000 monthly stipend and a one-time equity award valued at $250,000. Baxter reiterated its full-year 2026 financial outlook on August 19, 2026. The company operates in the global medical technology industry, providing hospital care solutions, medical devices, and injectable technologies.

Baxter International Inc. announced the pricing and early tender results for its cash tender offers of up to $600 million in aggregate principal amount of outstanding senior notes, including series due 2051, 2046, 2043, and 2032. The company increased the offer cap from $500 million to $600 million and accepted all tendered notes for priority levels one through three and approximately 31.37% of level four notes on a prorated basis. Total consideration per $1,000 principal ranges from $587.34 to $867.59, including an early tender premium of $30. Settlement is scheduled for August 20, 2026. Separately, Baxter entered into Amendment No. 2 to its five-year credit agreement, increasing the maximum net leverage ratio covenant for fiscal quarters through September 2027 and removing Baxter World Trade SRL as a borrower. Baxter International Inc. operates in the healthcare industry, providing medical devices, connected solutions, and advanced injectable technologies.

Baxter International Inc. announced that Anita Zielinski resigned as Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, and Controller, effective September 15, 2026, to join another company. The resignation was not due to any disagreement with management or the board regarding operations, policies, practices, financial disclosures, or accounting matters. Baxter International Inc. operates in the healthcare industry, providing medical products and services.

Baxter International Inc. announced the commencement of cash tender offers to purchase up to $500 million in aggregate principal amount of its outstanding senior notes, including series due 2032, 2043, 2046, and 2051. The company will accept tenders based on a priority waterfall methodology, prioritizing the 3.132% Notes due 2051 through the 2.539% Notes due 2032. An early tender premium of $30 per $1,000 principal amount is available for notes validly tendered by August 17, 2026. The offers expire on September 1, 2026, with settlement expected in late August or early September depending on the tender timing. This debt repurchase activity reflects the company's capital management strategy within the medical devices and healthcare solutions industry.

Baxter International Inc. reported second-quarter 2026 results with worldwide sales of $2.96 billion, a 5% increase on both a reported and organic basis. U.S. GAAP diluted earnings per share were $0.26, while adjusted diluted EPS was $0.56. The company raised its full-year 2026 financial outlook, projecting reported sales growth of 3% to 4%, organic sales growth of 2% to 3%, and adjusted EPS between $1.95 and $2.15. Additionally, the Board declared a quarterly cash dividend of $0.01 per share, payable on October 1, 2026, to stockholders of record as of August 28, 2026. Baxter International Inc. is a global medical technology company providing essential solutions in hospital and physician office settings.

Baxter International Inc. is recasting its historical segment and product category financial information to align with a new operating model effective for the second quarter of 2026. The company has transitioned from three reportable segments (Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals) to two segments: Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST). The former Pharmaceuticals segment is now integrated into the MPT segment's Infusion Therapies & Platforms (ITP) division. Baxter International Inc. operates in the medical technology and healthcare solutions industry, providing sterile IV solutions, infusion systems, and patient monitoring technologies.